AC Immune vs Aclaris Therapeutics
ACIU and ACRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACIU and ACRS compare
Aclaris Therapeutics grew revenue faster over the last twelve months (−59.3% versus −86.9% for AC Immune).
Aclaris Therapeutics scores higher on the StockData Score (6 against 3 for AC Immune), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACIU | ACRS |
|---|---|---|
| Size and price | ||
| Market cap | – | $577M |
| Share price | $2.13 | $3.92 |
| Change, 1 year | −35.1% | 62.7% |
| Change, 5 years | −61.1% | −71.6% |
| Beta (5Y) | 1.17 | 1.13 |
| Employees | 122 | 73 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 90.1× |
| P/B | – | 3.5× |
| FCF yield | – | −13.1% |
| Growth | ||
| Revenue growth (TTM) | −86.9% | −59.3% (better) |
| Revenue growth, 5Y average | −25.4% | 3.8% (better) |
| Profitability | ||
| Gross margin | – | 79.2% |
| Operating margin | −1940% | −1414% (better) |
| Net margin | – | −1244% |
| FCF margin | −1964% | −1177% (better) |
| Return on equity | – | −55.5% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −362.9× | – |
| Current ratio | 0.93 | 5.09 (better) |
| Altman Z-score | – | −0.44 |
| Piotroski F-score | – | 3 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 82.3% |
| Held by insiders | 23.6% | 13.3% |
| Insider net buying, 12 months | −$27.9K (better) | −$1.4M |
| Short interest, % of float | – | 9.1% |
Go deeper
- ACIU stock overview
- ACIU income statement
- ACIU valuation and score
- ACRS stock overview
- ACRS income statement
- ACRS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.